First Trust NYSE Arca Biotechnology Index Fund (FBT)

	Printer Friendly Page
	Fact Sheet
	Summary Prospectus
	Monthly Performance Report

Fund Summary

Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index^SM.

There can be no assurance that the Fund's investment objectives will be achieved.

The NYSE Arca Biotechnology Index^SM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent approximately equal weight in the index.

Fund Overview

Ticker	FBT
Fund Type	Biotechnology
Investment Advisor	First Trust Advisors L.P.
Investor Servicing Agent	Bank of New York
CUSIP	33733E203
Intraday NAV	FBTIV
Fiscal Year-End	12/31
Exchange	NYSE Arca
Inception	6/19/2006
Inception Price	$20.00
Inception NAV	$20.00
Gross Expense Ratio (12/31/2012)	0.61%
Net Expense Ratio	0.60%
Rebalance Frequency	Quarterly

Pursuant to contract, First Trust has agreed to waive fees and/or pay fund expenses to prevent the net expense ratio of the fund from exceeding 0.60% per year, at least until April 30, 2013.

Current Fund Data (as of 5/23/2013)

Closing NAV¹	$59.24
Closing Share Price²	$59.27
Bid/Ask Midpoint	$59.27
Bid/Ask Premium	0.05%
Total Net Assets	$346,564,944
Outstanding Shares	5,850,002
Daily Volume	93,782
Average 30-Day Daily Volume	56,910
Closing Share Price 52-Week High/Low	$61.44 / $41.19
Closing NAV 52-Week High/Low	$61.40 / $41.21
Number of Holdings	20

Fund Characteristics (as of 4/30/2013)³

Median Market Cap.	$6,409
Maximum Market Cap.	$80,367
Minimum Market Cap.	$262
Price/Earnings	23.69
Price/Book	4.76
Price/Cash Flow	25.51
Price/Sales	4.77

Top 10 Holdings (as of 5/24/2013)

Holding	Percent
Illumina, Inc.	6.07%
Immunogen, Inc.	5.78%
Regeneron Pharmaceuticals, Inc.	5.70%
Biogen Idec Inc.	5.60%
United Therapeutics Corporation	5.33%
Myriad Genetics, Inc.	5.32%
Alexion Pharmaceuticals, Inc.	5.19%
Incyte Corporation	5.13%
Gilead Sciences, Inc.	5.08%
Intermune Inc.	5.04%

Bid/Ask Midpoint and NAV History (Since Inception)

Past performance is not indicative of future results.

Volume (Since Inception)

Bid/Ask Midpoint vs. NAV (as of 3/31/2013)

Number of Days Bid/Ask Midpoint Above NAV

Quarter Ended	0-49 Basis Points	50-99 Basis Points	100-199 Basis Points	>=200 Basis Points
3/31/2013	45	0	0	0
12/31/2012	28	0	0	0
9/30/2012	33	0	0	0
6/30/2012	34	0	0	0

Number of Days Bid/Ask Midpoint Below NAV

Quarter Ended	0-49 Basis Points	50-99 Basis Points	100-199 Basis Points	>=200 Basis Points
3/31/2013	15	0	0	0
12/31/2012	34	0	0	0
9/30/2012	30	0	0	0
6/30/2012	29	0	0	0

The price used to calculate market return is determined by using the midpoint between the highest bid and the lowest offer on the stock exchange, on which shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated.

Month End Performance (as of 4/30/2013)

	3 Mos	YTD	1 Year	3 Year	5 Year	10 Year	Since Fund Inception⁴
Fund Performance *
NAV	16.17%	24.67%	30.39%	16.56%	20.28%	N/A	16.81%
After Tax Held	16.17%	24.67%	30.39%	16.56%	20.18%	N/A	16.74%
After Tax Sold	9.15%	13.96%	17.20%	13.05%	16.54%	N/A	13.91%
Market Price	16.27%	24.89%	30.45%	16.56%	20.26%	N/A	16.81%

Index Performance **
NYSE Arca Biotechnology Index	16.31%	24.89%	31.16%	17.30%	21.02%	17.89%	17.54%
NASDAQ® Biotechnology Index	18.40%	25.77%	38.48%	24.70%	18.11%	12.36%	14.68%
S&P 1500 Health Care Index	10.86%	19.18%	28.98%	18.01%	11.16%	8.21%	9.36%
S&P 500® Index	7.18%	12.74%	16.89%	12.80%	5.21%	7.88%	6.01%

Quarter End Performance (as of 3/28/2013)

	3 Mos	YTD	1 Year	3 Year	5 Year	10 Year	Since Fund Inception⁴
Fund Performance *
NAV	17.98%	17.98%	28.62%	13.52%	19.20%	N/A	16.08%
After Tax Held	17.98%	17.98%	28.62%	13.52%	19.10%	N/A	16.01%
After Tax Sold	10.18%	10.18%	16.20%	10.59%	15.61%	N/A	13.26%
Market Price	18.25%	18.25%	28.69%	13.56%	19.22%	N/A	16.09%

Index Performance **
NYSE Arca Biotechnology Index	18.11%	18.11%	29.41%	14.24%	19.94%	18.57%	16.80%
NASDAQ® Biotechnology Index	16.73%	16.73%	30.63%	21.72%	16.91%	12.80%	13.61%
S&P 1500 Health Care Index	15.76%	15.76%	24.94%	15.64%	10.92%	8.27%	9.01%
S&P 500® Index	10.61%	10.61%	13.96%	12.67%	5.81%	8.53%	5.78%

3-Year Statistics (as of 4/30/2013)

	Standard Deviation	Alpha	Beta	Sharpe Ratio	Correlation
First Trust NYSE Arca Biotechnology Index Fund	24.45%	3.42	1.13	0.72	0.69
NASDAQ® Biotechnology Index	17.59%	11.46	0.93	1.32	0.79
S&P 1500 Health Care Index	12.53%	7.83	0.71	1.34	0.86
S&P 500® Index	15.01%	---	---	0.84	---

Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.

*Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost. You can obtain performance information which is current through the most recent month-end by visiting ftportfolios.com.

After Tax Held returns represent return after taxes on distributions. Assumes shares have not been sold. After Tax Sold returns represent the return after taxes on distributions and the sale of fund shares. Returns do not represent the returns you would receive if you traded shares at other times. Market Price returns are based on the midpoint of the bid/ask spread. Returns are average annualized total returns, except those for periods of less than one year, which are cumulative. The fund's performance reflects fee waivers and expense reimbursements, absent which performance would have been lower.

After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

**Past performance is not a guarantee of future results. Performance information for the NYSE Arca Biotechnology Index is for illustrative purposes only and does not represent actual fund performance. No representation is being made that any investment will achieve performance similar to that shown. The Index does not charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown. Indexes are unmanaged and an investor cannot invest directly in an index. All index returns assume that dividends are reinvested when they are received.

The gross expense ratio for this fund is 0.61%. Pursuant to contract, First Trust has agreed to waive fees and/or pay fund expenses to prevent the net expense ratio of the fund from exceeding 0.60% per year, at least until April 30, 2013.

The NASDAQ Biotech Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.

The S&P Composite 1500 Health Care Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index.

The S&P 500 Index is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.

Footnotes

¹	The NAV represents the fund's net assets (assets less liabilities) divided by the fund's shares outstanding.
²	Fund shares are purchased and sold on an exchange at their share price rather than net asset value (NAV), which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount).
³	All market capitalization numbers are in USD$ Millions.
⁴	Inception Date is 6/19/2006

Downloads and Links to Recently Posted Fund Information

Fifth anniversary of First Trust NYSE Arca Biotechnology Index Fund – 8/8/2011
Click here to view all the downloads for this fund.

You should consider the fund's investment objectives, risks, and charges and expenses carefully before investing. You can download a prospectus or summary prospectus, or contact First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus or summary prospectus which contains this and other information about the fund. The prospectus or summary prospectus should be read carefully before investing.

ETF Characteristics

The fund lists and principally trades its shares on the NYSE Arca, Inc.

The fund's return may not match the return of the NYSE Arca Biotechnology Index. The fund may not be fully invested at times. Securities held by the fund will generally not be bought or sold in response to market fluctuations.

Investors buying or selling fund shares on the secondary market may incur customary brokerage commissions. Market prices may differ to some degree from the net asset value of the shares. Investors who sell fund shares may receive less than the share's net asset value. Shares may be sold throughout the day on the exchange through any brokerage account. However, unlike mutual funds, shares may only be redeemed directly from the fund by authorized participants, in very large creation/redemption units.

Risk Considerations

The fund's shares will change in value, and you could lose money by investing in the fund. One of the principal risks of investing in the fund is market risk. Market risk is the risk that a particular stock owned by the fund, fund shares or stocks in general may fall in value.

The fund may invest in small capitalization and mid capitalization companies. Such companies may experience greater price volatility than larger, more established companies.

The fund is concentrated in stocks of companies in the biotechnology sector. You should be aware that an investment in a portfolio which is concentrated in a particular sector involves additional risks, including limited diversification. The companies engaged in the biotechnology sector are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence.

The fund is classified as "non-diversified." A non-diversified fund generally may invest a larger percentage of its assets in the securities of a smaller number of issuers. As a result, the fund may be more susceptible to the risks associated with these particular companies, or to a single economic, political or regulatory occurrence affecting these companies.

The NYSE Arca Biotechnology Index^SM is a trademark of NYSE Euronext or its affiliates ("NYSE Euronext") and is licensed for use by First Trust. The fund is not sponsored or endorsed by NYSE Euronext. NYSE Euronext makes no representation or warranty, express or implied, to the owners of the fund or any member of the public regarding the advisability of investing in the fund or the ability of the fund to track the performance of the various sectors represented in the stock market. NYSE Euronext has no obligation to take the needs of the owners of the fund into consideration in determining, composing or calculating the index. NYSE Euronext is not responsible for and has not participated in any determination or calculation made with respect to issuance or redemption of the fund.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value